Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism

Summary

Although extended secondary prophylaxis with low-molecular-weight heparin was recently shown to be more effective than warfarin for cancer-related venous thromboembolism, its cost-effectiveness compared to traditional prophylaxis with warfarin is uncertain. We built a decision analytic model to evaluate the clinical and economic outcomes of a 6-month course of low-molecular-weight heparin or warfarin therapy in 65-year-old patients with cancer-related venous thromboembolism. We used probability estimates and utilities reported in the literature and published cost data. Using a US societal perspective, we compared strategies based on quality-adjusted life-years (QALYs) and lifetime costs. The incremental cost-effectiveness ratio of low-molecular-weight heparin compared with warfarin was $149, 865/QALY. Low-molecular-weight heparin yielded a quality-adjusted life expectancy of 1.097 QALYs at the cost of $15, 329. Overall, 46% ($7108) of the total costs associated with low-molecular-weight heparin were attributable to pharmacy costs. Although the low-molecular-weigh heparin strategy achieved a higher incremental quality-adjusted life expectancy than the warfarin strategy (difference of 0.051 QALYs), this clinical benefit was offset by a substantial cost increment of $7,609. Cost-effectiveness results were sensitive to variation of the early mortality risks associated with low-molecular-weight heparin and warfarin and the pharmacy costs for low-molecular-weight heparin. Based on the best available evidence, secondary prophylaxis with low-molecular-weight heparin is more effective than warfarin for cancer-related venous thromboembolism. However, because of the substantial pharmacy costs of extended low-molecular-weight heparin prophylaxis in the US, this treatment is relatively expensive compared with warfarin.

Keywords

Cost-effectiveness - treatment - cancer - venous thromboembolism

• References

• 1 Otten HM, Mathijssen J, Ten Cate H. et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med 2004; 164: 190-4.
• 2 Sorensen HT, Mellemkjaer L, Olsen JH. et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-50.
• 3 Hutten BA, Prins MH, Gent M. et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18: 3078-83.
• 4 Prandoni P, Lensing AW, Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-8.
• 5 British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax 2003; 58: 470-83.
• 6 Buller HR, Agnelli G, Hull RD. et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 401S-428S
• 7 Hull RD, Pineo GF, Mah AF. et al. A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Blood 2002; 100: 148a [Abstract]
• 8 Meyer G, Marjanovic Z, Valcke J. et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162: 1729-35.
• 9 Deitcher SR, Kessler CM, Merli G. et al. Secondary prevention of venous thromboembolic events in patients with active malignancy: a randomized study of enoxaparin sodium alone vs. initial enoxaparin sodium followed by warfarin for a 180-day period. J Thromb Haemost 2003; 1 Suppl OC194 [Abstract]
• 10 Lee AY, Levine MN, Baker I R. et al. Low-molecular- weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-53.
• 11 Levine M. Low-molecular-weight heparin or oral anticoagulation for secondary prevention of deep vein thrombosis in cancer patients. Semin Thromb Hemost 2003; 29 (Suppl. 01) 9-11.
• 12 Gold MR, Siegel JE, Russell LB. et al. Cost-Effectiveness in Health and Medicine. New York: Oxford University Pr; 1996
• 13 Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139: 893-900.
• 14 Lee AY, Julian JA, Levine MN. et al. Impact of dalteparin low-molecular-weight heparin on survival: Results of a randomized trial in cancer patients with venous thromboembolism. Proc Am Soc Clin Oncol 2003; 22: 846 [Abstract]
• 15 Cook N, Thomas DM. Retrospective survey of unselected hospital patients with and without cancer comparing outcomes following venous thromboembolism. Intern Med J 2002; 32: 437-44.
• 16 Beck JR, Pauker SG, Gottlieb JE. et al. A convenient approximation of life expectancy (the “DEALE“). II. Use in medical decision-making. Am J Med 1982; 73: 889-97.
• 17 Bronnum-Hansen H, Davidsen M, Thorvaldsen P. Long-term survival and causes of death after stroke. Stroke 2001; 32: 2131-6.
• 18 Carson JL, Kelley MA, Duff A. et al. The clinical course of pulmonary embolism. N Engl J Med 1992; 326: 1240-5.
• 19 Meneveau N, Ming LP, Seronde MF. et al. In-hospital and long-term outcome after sub-massive and massive pulmonary embolism submitted to thrombolytic therapy. Eur Heart J 2003; 24: 1447-54.
• 20 Kubba AK, Choudari C, Rajgopal C. et al. Reduced long-term survival following major peptic ulcer haemorrhage. Br J Surg 1997; 84: 265-8.
• 21 From the Medicare Provider Analysis and Review (MEDPAR) of Short-Stay Hospitals web site http://cms.hhs.gov/statistics/medpar/default.asp . Accessed December 13, 2003.
• 22 White RH, McKittrick T, Takakuwa J. et al. Management and prognosis of life-threatening bleeding during warfarin therapy. National Consortium of Anticoagulation Clinics. Arch Intern Med 1996; 156: 1197-201.
• 23 Gould MK, Dembitzer AD, Sanders GD. et al. Lowmolecular- weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med 1999; 130: 789-99.
• 24 Auerbach AD, Sanders GD, Hambleton J. Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies in patients with deep vein thrombosis. Am J Med 2004; 116: 816-28.
• 25 Aujesky D, Smith KJ, Roberts MS. Oral anticoagulation strategies after a first idiopathic venous thromboembolic event: a decision and cost-effectiveness analysis. Am J Med. (in press)
• 26 From the Centers for Medicare and Medicaid Services web site http://cms.hhs.gov/providers/pufdownload/default.asp . Accessed December 13, 2003.
• 27 Drug Topics Red Book Montvale, NY; Medical Economics: 2002
• 28 From the U.S. Bureau of Labor Statistics web site http://www.bls.gov/data/ . Accessed December 13, 2003.
• 29 Taylor TN, Davis PH, Torner JC. et al. Lifetime cost of stroke in the United States. Stroke 1996; 27: 1459-66.
• 30 Caprini JA, Botteman MF, Stephens JM. et al. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value Health 2003; 6: 59-74.
• 31 Doubilet P, Begg CB, Weinstein MC. et al. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 1985; 5: 157-77.
• 32 Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998; 18: S68-80.
• 33 Mark DB, Hlatky MA, Califf RM. et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1418-24.
• 34 From the British National Formulary website www.bnf.org . Accessed February 15, 2004.
• 35 From the French Formulary website www.vidal.fr . Accessed February 16, 2004.
• 36 From the Swiss Drug Formulary www.documed.ch . Accessed February 15, 2004.
• 37 From the Ontario Drug Benefit Formulary/Comparative Drug Index website www.health.gov.on.ca/english/providers/program/drugs/odbf_mn.html . Accessed February 15, 2004.
• 38 Marchetti M, Pistorio A, Barone M. et al. Low-molecular- weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. Am J Med 2001; 111: 130-9.
• 39 Elting LS, Escalante CP, Cooksley C. et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004; 164: 1653-61.
• 40 Gold M, Franks P, Erickson P. Assessing the health of the nation. The predictive validity of a preferencebased measure and self-rated health. Med Care 1996; 34: 163-77.
• 41 Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. J Am Med Inform Assoc 1997; 4: 49-56.
• 42 Gage BF, Cardinalli AB, Albers GW. et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995; 274: 1839-45.